<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657016</url>
  </required_header>
  <id_info>
    <org_study_id>17246</org_study_id>
    <secondary_id>I8F-MC-GPHM</secondary_id>
    <nct_id>NCT04657016</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program</brief_title>
  <acronym>SURMOUNT-3</acronym>
  <official_title>Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of tirzepatide in participants with obesity. The purpose of this study is to&#xD;
      learn more about how tirzepatide maintains body weight or adds to weight loss after an&#xD;
      intensive lifestyle modification program. The study will last about 2 years (29 visits).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">June 8, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Randomization in Body Weight</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Percent change from randomization in body weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with ≥5% Body Weight Reduction</measure>
    <time_frame>72 Weeks</time_frame>
    <description>Percentage of participants with ≥5% body weight reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Maintain ≥80% of the Body Weight Lost During Intensive Lifestyle Program</measure>
    <time_frame>72 Weeks</time_frame>
    <description>Percentage of participants who maintain ≥80% of the body weight lost during intensive lifestyle program</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥10%Body Weight Reduction</measure>
    <time_frame>72 Weeks</time_frame>
    <description>Percentage of participants who achieve ≥10% body weight reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥15% Body Weight Reduction</measure>
    <time_frame>72 Weeks</time_frame>
    <description>Percentage of participants who achieve ≥15% body weight reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Waist Circumference</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in waist circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Body Weight</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Body Mass Index (BMI)</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Systolic Blood Pressure (SBP)</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Total Cholesterol</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in High Density Lipoprotein (HDL) Cholesterol</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in HDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Low Density Lipoprotein (LDL) Cholesterol</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in LDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Very Low Density Lipoprotein (VLDL) Cholesterol</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in VLDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Triglycerides</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Free Fatty Acids</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in free fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Fasting Glucose</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in HbA1c</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Fasting Insulin</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>Change from randomization in fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Short Form 36 Version 2 Health Survey (SF 36v2) Acute Form Physical Functioning Domain Score</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>The Short Form 36 Version 2 (SF-36v2) acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains; 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning 7) limitations in usual role due to emotional problems; and 8) general mental health. Domain scores are norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10, with higher scores indicating better levels of function and/or better health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Randomization in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL) Lite CT Physical Function Composite Score</measure>
    <time_frame>Randomization, 72 Weeks</time_frame>
    <description>The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5 item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Absolute Body Weight</measure>
    <time_frame>Baseline, 72 Weeks</time_frame>
    <description>Change from baseline in absolute body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Body Weight</measure>
    <time_frame>Baseline, 72 Weeks</time_frame>
    <description>Percent change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BMI</measure>
    <time_frame>Baseline, 72 Weeks</time_frame>
    <description>Change from baseline in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Waist Circumference</measure>
    <time_frame>Baseline, 72 Weeks</time_frame>
    <description>Change from baseline in waist circumference</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Tirzepatide</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 and previously diagnosed with at&#xD;
             least 1 of the following comorbidities: hypertension, dyslipidemia, obstructive sleep&#xD;
             apnea or cardiovascular disease&#xD;
&#xD;
          -  History of at least one unsuccessful dietary effort to lose body weight&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Change in body weight greater than 5 kg within 3 months prior to starting study&#xD;
&#xD;
          -  Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of&#xD;
             obesity&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine&#xD;
             neoplasia syndrome type 2 (MEN-2)&#xD;
&#xD;
          -  History of significant active or unstable major depressive disorder (MDD) or other&#xD;
             severe psychiatric disorder within the last 2 years&#xD;
&#xD;
          -  Any lifetime history of a suicide attempt&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute (NRI) - Santa Ana</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Encompass Clinical Research</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizon Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute, Inc.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Trials</name>
      <address>
        <city>Blackfoot</city>
        <state>Idaho</state>
        <zip>83221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solaris Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Trials</name>
      <address>
        <city>Rexburg</city>
        <state>Idaho</state>
        <zip>83440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Premier Healthcare Research LLC</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of IN, LLC</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of IN, LLC</name>
      <address>
        <city>Franklin</city>
        <state>Indiana</state>
        <zip>46131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of IN, LLC</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Mulvane</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research,LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National Diabetes &amp; Obesity Research Institute</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinvest Research LLC</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Research Center Sunset</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center (WFUBMC)</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intend Research, LLC</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detweiler Family Medicine &amp; Associates</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Medicine: University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tribe Clinical Research, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Health One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Endocrinology Associates</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology, P.A.</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consano Clinical Research, LLC</name>
      <address>
        <city>Shavano Park</city>
        <state>Texas</state>
        <zip>78231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc.</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Institute for Research &amp; Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Viamonte</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1120AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones Medicas Imoba Srl</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1179AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Centenario</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1204AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Metabólicas (CINME)</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>1056</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stat Research S.A.</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>C1023AAB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenny Corp</name>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Autónoma De Buenos Aire</state>
        <zip>1430</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEMEDIAB</name>
      <address>
        <city>C.a.b.a.</city>
        <state>Ciudad Autónoma De Buenos Aire</state>
        <zip>C1205AAO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Médico Especializado (IME)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1405</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Norte</name>
      <address>
        <city>Santiago del Estero</city>
        <zip>4200</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEDOES</name>
      <address>
        <city>Vitória</city>
        <state>Espírito Santo</state>
        <zip>29055450</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cline Research Center</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80030-480</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quanta Diagnóstico e Terapia</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80040-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPCLIN</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>01228-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BR Trials - Ensaios Clinicos e Consultoria</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>03325-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IBPClin - Instituto Brasil de Pesquisa Clínica</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22241-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPQuali Pesquisa Clínica</name>
      <address>
        <city>São Paulo</city>
        <zip>01228-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEPIC - Centro Paulista de Investigação Clínica</name>
      <address>
        <city>São Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research, LLC</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manati Center for Clinical Research</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School Foundation Inc.</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/1ZuH7WHjpse8JDpVFSSi1I</url>
    <description>A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (SURMOUNT-3)</description>
  </link>
  <verification_date>October 1, 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diet</keyword>
  <keyword>Exercise</keyword>
  <keyword>Metabolism and Nutrition Disorder</keyword>
  <keyword>Behavioral Modification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirzepatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan Description:&#xD;
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>Access Criteria:&#xD;
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

